Caricamento...
5PSQ-010 Efficacy and safety of agalsidase alfa in fabry disease
BACKGROUND: Fabry disease is included within the lipid deposition diseases that occur due to mutations in the gene that encodes the α-galactosidase enzyme. As a consequence, a fatty substance, globotriosilceramide (GL-3), is responsible for the illness of different organs such as the heart, eyes or...
Salvato in:
| Pubblicato in: | Eur J Hosp Pharm |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMJ Group
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535223/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.364 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|